Brief Communication | Published:

AAV1.NT-3 gene therapy increases muscle fiber diameter through activation of mTOR pathway and metabolic remodeling in a CMT mouse model

Abstract

Neurotrophin 3 (NT-3) has well-recognized effects on peripheral nerve and Schwann cells, promoting axonal regeneration and associated myelination. In this study, we assessed the effects of AAV.NT-3 gene therapy on the oxidative state of the neurogenic muscle from the TremblerJ (TrJ) mice at 16 weeks post-gene injection and found that the muscle fiber size increase was associated with a change in the oxidative state of muscle fibers towards normalization of the fiber type ratio seen in the wild type. NT-3-induced fiber size increase was most prominent for the fast twitch glycolytic fiber population. These changes in the TrJ muscle were accompanied by increased phosphorylation levels of 4E-BP1 and S6 proteins as evidence of mTORC1 activation. In parallel, the expression levels of the mitochondrial biogenesis regulator PGC1α, and the markers of glycolysis (HK1 and PK1) increased in the TrJ muscle. In vitro studies showed that recombinant NT-3 can directly induce Akt/mTOR pathway activation in the TrkC expressing myotubes but not in myoblasts. In addition, myogenin expression levels were increased in myotubes while p75NTR expression was downregulated compared to myoblasts, indicating that NT-3 induced myoblast differentiation is associated with mTORC1 activation. These studies for the first time have shown that NT-3 increases muscle fiber diameter in the neurogenic muscle through direct activation of mTOR pathway and that the fiber size increase is more prominent for fast twitch glycolytic fibers.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Sekimoto M, Tsuji T, Matsuzaki J, Chamoto K, Koda T, Nemoto K, et al. Functional expression of the TrkC gene, encoding a high affinity receptor for NT-3, in antigen-specific T helper type 2 (Th2) cells. Immunol Lett. 2003;88:221–6.

  2. 2.

    Beutner C, Lepperhof V, Dann A, Linnartz-Gerlach B, Litwak S, Napoli I, et al. Engineered stem cell-derived microglia as therapeutic vehicle for experimental autoimmune encephalomyelitis. Gene Ther. 2013;20:797–806.

  3. 3.

    Yang J, Yan Y, Xia Y, Kang T, Li X, Ciric B, et al. Neurotrophin 3 transduction augments remyelinating and immunomodulatory capacity of neural stem cells. Mol Ther. 2014;22:440–50.

  4. 4.

    Yalvac ME, Arnold WD, Braganza C, Chen L, Mendell JR, Sahenk Z. AAV1.NT-3 gene therapy attenuates spontaneous autoimmune peripheral polyneuropathy. Gene Ther. 2015;23:95–102.

  5. 5.

    Sahenk Z, Galloway G, Clark KR, Malik V, Rodino-Klapac LR, Kaspar BK, et al. AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy. Mol Ther. 2014;22:511–21.

  6. 6.

    Nicks JR, Lee S, Kostamo KA, Harris AB, Sookdeo AM, Notterpek L. Long-term analyses of innervation and neuromuscular integrity in the Trembler-J mouse model of Charcot-Marie-tooth disease. J Neuropathol Exp Neurol. 2013;72:942–54.

  7. 7.

    Miljkovic N, Lim JY, Miljkovic I, Frontera WR. Aging of skeletal muscle fibers. Ann Rehabil Med. 2015;39:155–62.

  8. 8.

    Alnaqeeb MA, Goldspink G. Changes in fibre type, number and diameter in developing and ageing skeletal muscle. J Anat. 1987;153:31–45.

  9. 9.

    Brunner F, Schmid A, Sheikhzadeh A, Nordin M, Yoon J, Frankel V. Effects of aging on Type II muscle fibers: a systematic review of the literature. J Aging Phys Act. 2007;15:336–48.

  10. 10.

    Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–93.

  11. 11.

    Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009;10:307–18.

  12. 12.

    Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39:171–83.

  13. 13.

    Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892–9.

  14. 14.

    Morita M, Gravel SP, Chenard V, Sikstrom K, Zheng L, Alain T, et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 2013;18:698–711.

  15. 15.

    Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol Rev. 2011;91:1447–531.

  16. 16.

    Schecterson LC, Bothwell M. Novel roles for neurotrophins are suggested by BDNF and NT-3 mRNA expression in developing neurons. Neuron. 1992;9:449–63.

  17. 17.

    Yamamoto M, Sobue G, Yamamoto K, Terao S, Mitsuma T. Expression of mRNAs for neurotrophic factors (NGF, BDNF, NT-3, and GDNF) and their receptors (p75NGFR, trkA, trkB, and trkC) in the adult human peripheral nervous system and nonneural tissues. Neurochem Res. 1996;21:929–38.

  18. 18.

    Seidl K, Erck C, Buchberger A. Evidence for the participation of nerve growth factor and its low-affinity receptor (p75NTR) in the regulation of the myogenic program. J Cell Physiol. 1998;176:10–21.

  19. 19.

    Erck C, Meisinger C, Grothe C, Seidl K. Regulation of nerve growth factor and its low-affinity receptor (p75NTR) during myogenic differentiation. J Cell Physiol. 1998;176:22–31.

  20. 20.

    Reddypalli S, Roll K, Lee HK, Lundell M, Barea-Rodriguez E, Wheeler EF. p75NTR-mediated signaling promotes the survival of myoblasts and influences muscle strength. J Cell Physiol. 2005;204:819–29.

  21. 21.

    Sterne GD, Coulton GR, Brown RA, Green CJ, Terenghi G. Neurotrophin-3-enhanced nerve regeneration selectively improves recovery of muscle fibers expressing myosin heavy chains 2b. J Cell Biol. 1997;139:709–15.

  22. 22.

    Izumiya Y, Hopkins T, Morris C, Sato K, Zeng L, Viereck J, et al. Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab. 2008;7:159–72.

  23. 23.

    Risson V, Mazelin L, Roceri M, Sanchez H, Moncollin V, Corneloup C, et al. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J Cell Biol. 2009;187:859–74.

  24. 24.

    Tsai S, Sitzmann JM, Dastidar SG, Rodriguez AA, Vu SL, McDonald CE, et al. Muscle-specific 4E-BP1 signaling activation improves metabolic parameters during aging and obesity. J Clin Invest. 2015;125:2952–64.

  25. 25.

    Hohn A, Leibrock J, Bailey K, Barde YA. Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family. Nature. 1990;344:339–41.

  26. 26.

    Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, et al. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science. 1990;247(4949 Pt 1):1446–51.

  27. 27.

    Lohof AM, Ip NY, Poo MM. Potentiation of developing neuromuscular synapses by the neurotrophins NT-3 and BDNF. Nature. 1993;363:350–3.

  28. 28.

    Wang T, Xie K, Lu B. Neurotrophins promote maturation of developing neuromuscular synapses. J Neurosci. 1995;15(7 Pt 1):4796–805.

  29. 29.

    Xie K, Wang T, Olafsson P, Mizuno K, Lu B. Activity-dependent expression of NT-3 in muscle cells in culture: implications in the development of neuromuscular junctions. J Neurosci. 1997;17:2947–58.

  30. 30.

    Fu AK, Ip FC, Lai KO, Tsim KW, Ip NY. Muscle-derived neurotrophin-3 increases the aggregation of acetylcholine receptors in neuron-muscle co-cultures. Neuroreport. 1997;8:3895–900.

  31. 31.

    Mirsky R, Jessen KR, Brennan A, Parkinson D, Dong Z, Meier C, et al. Schwann cells as regulators of nerve development. J Physiol Paris. 2002;96:17–24.

  32. 32.

    Frostick SP, Yin Q, Kemp GJ. Schwann cells, neurotrophic factors, and peripheral nerve regeneration. Microsurgery. 1998;18:397–405.

  33. 33.

    Meier C, Parmantier E, Brennan A, Mirsky R, Jessen KR. Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. J Neurosci. 1999;19:3847–59.

  34. 34.

    Lindsay RM. Therapeutic potential of the neurotrophins and neurotrophin-CNTF combinations in peripheral neuropathies and motor neuron diseases. Ciba Found Symp . 1996;196:39–48. discussion48-53

  35. 35.

    Sterne GD, Brown RA, Green CJ, Terenghi G. Neurotrophin-3 delivered locally via fibronectin mats enhances peripheral nerve regeneration. Eur J Neurosci. 1997;9:1388–96.

  36. 36.

    Sahenk Z, Oblinger J, Edwards C. Neurotrophin-3 deficient Schwann cells impair nerve regeneration. Exp Neurol. 2008;212:552–6.

  37. 37.

    Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology. 2005;65:681–9.

  38. 38.

    Narayanan SP, Flores AI, Wang F, Macklin WB. Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci. 2009;29:6860–70.

  39. 39.

    Tyler WA, Gangoli N, Gokina P, Kim HA, Covey M, Levison SW, et al. Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci. 2009;29:6367–78.

  40. 40.

    Bibollet-Bahena O, Almazan G. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways. J Neurochem. 2009;109:1440–51.

  41. 41.

    Coelho RP, Yuelling LM, Fuss B, Sato-Bigbee C. Neurotrophin-3 targets the translational initiation machinery in oligodendrocytes. Glia. 2009;57:1754–64.

  42. 42.

    Sherman DL, Krols M, Wu LM, Grove M, Nave KA, Gangloff YG, et al. Arrest of myelination and reduced axon growth when Schwann cells lack mTOR. J Neurosci. 2012;32:1817–25.

  43. 43.

    Young C, Miller E, Nicklous DM, Hoffman JR. Nerve growth factor and neurotrophin-3 affect functional recovery following peripheral nerve injury differently. Restor Neurol Neurosci. 2001;18:167–75.

  44. 44.

    Colombo E, Romaggi S, Medico E, Menon R, Mora M, Falcone C, et al. Human neurotrophin receptor p75NTR defines differentiation-oriented skeletal muscle precursor cells: implications for muscle regeneration. J Neuropathol Exp Neurol. 2011;70:133–42.

  45. 45.

    Toti P, Villanova M, Vatti R, Schuerfeld K, Stumpo M, Barbagli L, et al. Nerve growth factor expression in human dystrophic muscles. Muscle Nerve. 2003;27:370–3.

  46. 46.

    Bentzinger CF, Romanino K, Cloetta D, Lin S, Mascarenhas JB, Oliveri F, et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. 2008;8:411–24.

  47. 47.

    Yalvac ME, Amornvit J, Braganza C, Chen L, Hussain SA, Shontz KM, et al. Impaired regeneration in calpain-3 null muscle is associated with perturbations in mTORC1 signaling and defective mitochondrial biogenesis. Skelet Muscle. 2017;7:27.

  48. 48.

    Griffin DA, Johnson RW, Whitlock JM, Pozsgai ER, Heller KN, Grose WE, et al. Defective membrane fusion and repair in Anoctamin5-deficient muscular dystrophy. Hum Mol Genet. 2016;25:1900–11.

  49. 49.

    Chiu YH, Hornsey MA, Klinge L, Jorgensen LH, Laval SH, Charlton R, et al. Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet. 2009;18:1976–89.

  50. 50.

    Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol Ther. 2017;25:870–9.

  51. 51.

    Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. 2007;450:736–40.

  52. 52.

    Toscano MG, Delgado M, Kong W, Martin F, Skarica M, Ganea D. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther. 2010;18:1035–45.

  53. 53.

    Wang X, Spandidos A, Wang H, Seed B. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res. 2012;40:D1144–9.

Download references

Author information

Supported by an internal grant from Research Institute in Nationwide Children’s Hospital (Z.S).

Conflict of interest

The authors declare that they have no conflict of interest.

Correspondence to Zarife Sahenk.

Electronic supplementary material

  1. Supplementary Figure S1

  2. Supplementary Figure S2

  3. Supplementary Figure S3

  4. Supplementary Figure S4

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1
Fig. 2
Fig. 3